Clinical characteristics associated with mortality of patients with anaerobic bacteremia

Anaerobe
Takumi UmemuraHiroshige Mikamo

Abstract

The presence of anaerobes in the blood stream is known to be associated with a higher rate of mortality. However, few prognostic risk factor analyses examining whether a patient's background characteristics are associated with the prognosis have been reported. We performed a retrospective case-controlled study to assess the prognostic factors associated with death from anaerobic bacteremia. Seventy-four patients with anaerobic bacteremia were treated between January 2005 and December 2014 at Aichi Medical University Hospital. The clinical information included drug susceptibility was used for analysis of prognostic factors for 30-day mortality. Multivariate logistic analyses revealed an association between the 30-day mortality rate and malignancy (OR: 3.64, 95% CI: 1.08-12.31) and clindamycin resistance (OR: 7.93, 95% CI: 2.33-27.94). The result of Kaplan-Meier analysis of mortality showed that the 30-day survival rate was 83% in clindamycin susceptible and 38.1% in clindamycin resistant anaerobes causing bacteremia. The result of log-rank test also showed that susceptibility to clindamycin affected mortality (P < 0.001). Our results indicated that malignancy and clindamycin susceptibility could be used to identify subgroups of ...Continue Reading

References

Jun 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·V A PerainoE J Goldstein
Jun 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H SalonenO Meurman
Jun 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M H NguyenD R Snydman
Nov 25, 2000·International Journal of Antimicrobial Agents·H Giamarellou
Jul 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R L LarkC Chenoweth
Oct 15, 2003·The Journal of Infection·Charalambos A GogosHarry P Bassaris
Mar 17, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J R Wilson, A P Limaye
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Liliana SimonJacques Lacroix
Feb 1, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P PóvoaH Sabino
Aug 18, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J-R ZaharG Nitenberg
Mar 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Britta LassmannJon E Rosenblatt
Aug 25, 2010·Antimicrobial Agents and Chemotherapy·Mical PaulLeonard Leibovici
Jun 9, 2012·Anaerobe·Anilrudh A VenugopalLeonard B Johnson
May 13, 2014·European Journal of Internal Medicine·Ana EsparciaJosé M Nogueira
Jun 4, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D Rodríguez-PardoA Pahissa
Jul 16, 2014·Infection & chemotherapy·Hye Won KimYoung Goo Song

❮ Previous
Next ❯

Citations

May 17, 2017·Revista Argentina de microbiología·Silvia C PredariLiliana Castello
Oct 1, 2019·Current Opinion in Infectious Diseases·Louise Cooley, Jasmine Teng
Apr 5, 2020·Anaerobe·Sarah StablerRémi Le Guern
Jun 27, 2020·European Journal of Microbiology & Immunology·Márió Gajdács, Edit Urbán
Oct 28, 2021·The Journal of International Medical Research·Yang YangTaohong Lu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.